Multiomic

multi-omics, AI, precision medicine

discoverydiscovering

multiomic.health·London, United Kingdom·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-YYVQ

Projects

AI-enabled multi-omics precision medicine platform

undisclosed

platform · high

Identify patient subpopulations in age-related chronic multifactorial diseases and support development of therapeutics with companion diagnostics.

Uses deep longitudinal patient datasets, AI-enabled data science, experimental biology, multiple omics modalities, and longitudinal clinical phenotyping.

Platform built; initial disease focus is cardio-renal-metabolic disease with chronic kidney disease as the first platform use case.

Cardio-renal-metabolic disease precision medicines program

undisclosed

research program · medium

Discover and develop precision medicines for cardio-renal-metabolic disease.

Multi-omics, AI-enabled data science, longitudinal patient datasets, longitudinal clinical phenotyping, and experimental biology.

Declared as the company's initial therapeutic focus area.

Chronic kidney disease precision medicine program

exploratory

research program · medium

Apply Multiomic Health's platform to chronic kidney disease to identify patient subpopulations and enable therapeutic development with companion diagnostics.

AI-enabled analysis of longitudinal clinical phenotyping and multi-omics data, combined with experimental biology.

Identified as the company's first platform use case.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence